Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01550406
Other study ID # PFDP-2011
Secondary ID
Status Completed
Phase Phase 4
First received November 21, 2011
Last updated June 6, 2016
Start date November 2011

Study information

Verified date June 2016
Source Seoul National University Hospital
Contact n/a
Is FDA regulated No
Health authority Korea: Ministry for Health and Welfare
Study type Interventional

Clinical Trial Summary

To date, there has been many methods suggested to reduce pancreatic fistula. But there are no evidence of superiority to the other methods. This study is a multicenter prospective randomized phase III study of use of Tachocomb or Polyethylene Glycolic Acid (PGA) to prevent of pancreatic fistula after distal pancreatectomy.


Description:

Distal pancreatectomy has been called to by various names such as, left-sided pancreatectomy, distal partial pancreatectomy. It is difficult to define which part of the pancreas as distal in exactly, but typically the superior mesenteric vein (SMV) and splenic vein, come to meet portal vein to form the area that covers the pancreas, neck actually based on a relatively thin pancreatic resection area, if left to its distal pancreatic resection is generally defined as that.

Indication of distal pancreatectomy in Western countries have been trauma (16%), pancreas cancer (18%), neuroendocrine tumors (14%), chronic pancreatitis (24%), other benign disease (22%) and in Korea, in contrast, disease caused by inflammatory process such as chronic pancreatitis has had relatively low incidence. But the rate of combined resection of distal pancreas at the time of gastric surgery was relatively high.

Definitions and names of pancreatic fistula have been reported differently in each center. Heidelberg and Johns Hopkins groups defined pancreatic fistula as drain amylase levels more than three times of normal serum value , and with more than 50mL during 24 hours after postoperative 10 days. German and Italian groups defined that as drain amylase levels more than three times of normal serum value, and with more than 10mL during 24 hours after postoperative 3-4 days. Japanese group defined pancreatic fistula as drain amylase levels more than three times of normal serum value, and with persistent drainage after postoperative 7 days. Lowy et al defined clinically significant pancreatic fistula as 38℃ or more of fever and leukocytosis (> 10,000 cells/mm3), and sepsis associated or necessity of drainage of abdominal fluid.

To adjust this various criteria, International Study Group Pancreatic Fistula (ISGPF) 2005 defined pancreatic fistula as drain amylase levels more than three times of normal serum value at the time of postoperative 3 days, and divided severity by 3 category with A to C in accordance with clinical course.

As followed previous studies, pancreatic fistula has been one of major postoperative complications (13-64%), which is leading cause of intra-abdominal infections, abscesses, septicemia, wound infection, postoperative bleeding, and malnutrition Risk factors related pancreas fistula have been presented as a disease- associated factors (pancreatic hardness, pathological findings, diameter of main p- duct, and the thickness of pancreas resection area), surgery-related factors (method of pancreas resection, intraoperative blood loss, operative time, blood transfusion during surgery), patient-related factors (age, sex, race, comorbidity) and the experience of surgeon, etc.

Based on experience and observation of the above listed risk factors for pancreatic fistula, there has been rarely reported that the incidence of pancreatic fistula was markedly reduced by some kind of methods.

As mentioned above, one of the risk factors of pancreatic fistula is operative method or technique. To date, there has been many methods suggested to reduce pancreatic fistula. For example, as dealing with pancreas cut surface, there has been several methods, such as, hand-sewn suture techniques, stapled closure, the use of fibrin glue, the use of mesh. But there are few evidence of superiority to the other methods.

Recent retrospective studies suggested the usefulness of mesh that the incidence of pancreatic fistula with mesh (5.6-27%) was lower than without mesh (38.9~42.0%).

There are two kind of mesh to use surgical fields, that are PGA and tachocomb. Among that, the methods with PGA has been reported in a few retrospective study. Moreover, there are no report about the effectiveness with Tachocomb.

The objective of this prospective multicenter randomized study is to clarify the proper method to reduce pancreatic fistula by PGA or tachocomb.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date
Est. primary completion date April 2015
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 84 Years
Eligibility Inclusion Criteria:

- Expected survival time more than 12 months

- Patients with at least one of the following pathologic diseases scheduled for elective resection

- Resectable malignancies of the pancreatic body/ tail

- Resectable pre-malignant lesions of the pancreatic body/ tail

- Resectable benign lesion of the pancreatic body/ tail

Exclusion Criteria:

- Current immunosuppressive therapy

- Pancreatic atrophy or calcification due to severe pancreatitis

- Chemotherapy or radiotherapy before operation

- Severe psychiatric or neurologic diseases

- Drug- and/or alcohol-abuse according to local standards

- Participation in another intervention trial with interference of a primary or secondary endpoint of this study

- Inability to follow the instructions given by the investigator

- Lack of compliance

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Device:
Tachocomb
A kind of Mesh: ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin
Polyglycolic acid (PGA) (Neoveil)
Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.

Locations

Country Name City State
Korea, Republic of Seoul National University Bundang Hospital Seongnam Bundang-gu
Korea, Republic of Department of Surgery, Seoul National University College of Medicine Seoul
Korea, Republic of Gangnam Severance Hospital Seoul
Korea, Republic of Samsung Medical Center Seoul
Korea, Republic of Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Seoul National University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The rate of pancreatic fistula between groups Pancreatic fistula was defined by criterion of ISGPF, Output through an operatively placed drain or a subsequently placed percutaneous drain, of any measurable volume of drain fluid on or after postoperative day 3, with an amylase content greater than three times the upper normal serum value postoperative 3rd day No
Secondary Surgery-related risk factor Amount of intraoperative bleeding, blood transfusion, operative time, operative method with open, laparoscopic, or robotic surgery intraoperative time No
Secondary disease- associated factors pancreatic hardness, pathological findings, diameter of main p- duct, and the thickness of pancreas resection area intraoperative time, within 1 day after operation No
Secondary patient-related risk factors analysis age, sex, race, comorbidity 1 week before the operation No
See also
  Status Clinical Trial Phase
Completed NCT01696903 - Evaluation of a Novel Pancreaticojejunostomy Technique for Pancreaticoduodenectomy N/A
Completed NCT01301222 - Role of Octreotide in Preventing Pancreatic Fistula After Pancreaticoduodenectomy (PD) in Patients With Soft Pancreas Phase 4
Recruiting NCT05155878 - Prognostic Factors in Periampullary Tumors and Cysts
Terminated NCT03757455 - ERAS Protocol in Pancreaticoduodenectomy and Total Pancreatectomy N/A
Recruiting NCT05212350 - Total pancrEaTectomy vs High-Risk Pancreatic anastomosiS N/A
Completed NCT04609137 - Early Drain Removal Versus Standard Drain Management After Distal Pancreatectomy (Early-Dist) N/A
Recruiting NCT04798560 - Identifing Risk Factors for Pancreaticojejunostomy Leakage Following Pancreaticoduodenectomy
Completed NCT03627559 - Early Detection of Anastomotic Leakage by Microdialysis Catheters
Recruiting NCT04783831 - Biodegradable Pancreatic Stents for the Prevention of Postoperative Pancreatic Fistula After Cephalic Pancreaticoduodenectomy
Not yet recruiting NCT05387538 - One-layer Versus Two-layer Duct-to-mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy . N/A
Active, not recruiting NCT02775227 - HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications Phase 4
Completed NCT02790333 - Different Stapler Cartridge For Pancreatic Stump Texture To Prevent Pancreatic Fistula N/A
Not yet recruiting NCT05657366 - Peritoneal Lavage on the Incidence of Pancreatic Fistula and Related Complications After Pancreatoduodenectomy N/A
Completed NCT03419676 - Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy Phase 3
Recruiting NCT05297136 - Preoperative Endoscopic Pancreatic Stent for Distal Pancreatectomy N/A
Completed NCT00931554 - Randomized Trial of Early Versus Standard Drainage Removal After Pancreatic Resections N/A
Completed NCT00679952 - Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy Phase 3
Recruiting NCT04380506 - Validations of New cut-of for the Stratification of Postoperative Complications,Drains Management N/A
Recruiting NCT06283160 - Metabolomic and Immune Profiling in the Development of Pancreatic Fistulas After Cephalic Duodenopancreatectomy
Completed NCT02784990 - Study of Pancreatic Enzymes in the Drains as Early Biomarkers of Post-operative Pancreatic Fistula and Its Clinical Repercussions